Tags

Type your tag names separated by a space and hit enter

Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women.
Metabolism. 2010 May; 59(5):742-7.M

Abstract

Osteoprotegerin (OPG) is an inhibitor of bone resorption. Circulating levels of OPG seem to be elevated in patients with cardiovascular disorders and diabetes. The relationship between OPG and the metabolic syndrome has never been studied in postmenopausal women. In a population-based study, 382 Iranian postmenopausal women were randomly selected. Cardiovascular risk factors, high-sensitivity C-reactive protein, and OPG were measured. The diabetes classification and the metabolic syndrome definition were based on the criteria of the American Diabetes Association and the National Cholesterol Education Program-Adult Treatment Panel III, respectively. The mean serum OPG level was higher in those with type 2 diabetes mellitus than those without diabetes (4.33 +/- 1.70 vs 3.84 +/- 1.76 pmol/L, P = .016). In multiple logistic regression analysis, type 2 diabetes mellitus showed a significant association with serum OPG levels when adjustments were made for age, high-sensitivity C-reactive protein, and cardiovascular risk factors (odds ratio = 2.21; confidence interval, 1.34-3.66; P = .002). No significant difference was found between the mean serum OPG levels of those with the metabolic syndrome and those without the metabolic syndrome. Mean OPG levels did not differ significantly between subjects with and without hypertension, dyslipidemia, glucose intolerance, or abdominal obesity according to the National Cholesterol Education Program-Adult Treatment Panel III criteria. In conclusion, circulating OPG levels are significantly associated with diabetes, independent of cardiovascular risk factors in postmenopausal women. However, OPG levels have no correlation with the metabolic syndrome or its components. Further studies are warranted to determine the pathophysiologic origin of elevated OPG in type 2 diabetes mellitus.

Authors+Show Affiliations

Department of Endocrine and Metabolic Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran. inabipour@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19922962

Citation

Nabipour, Iraj, et al. "Osteoprotegerin in Relation to Type 2 Diabetes Mellitus and the Metabolic Syndrome in Postmenopausal Women." Metabolism: Clinical and Experimental, vol. 59, no. 5, 2010, pp. 742-7.
Nabipour I, Kalantarhormozi M, Larijani B, et al. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism. 2010;59(5):742-7.
Nabipour, I., Kalantarhormozi, M., Larijani, B., Assadi, M., & Sanjdideh, Z. (2010). Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism: Clinical and Experimental, 59(5), 742-7. https://doi.org/10.1016/j.metabol.2009.09.019
Nabipour I, et al. Osteoprotegerin in Relation to Type 2 Diabetes Mellitus and the Metabolic Syndrome in Postmenopausal Women. Metabolism. 2010;59(5):742-7. PubMed PMID: 19922962.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. AU - Nabipour,Iraj, AU - Kalantarhormozi,Mohammadreza, AU - Larijani,Bagher, AU - Assadi,Majid, AU - Sanjdideh,Zahra, Y1 - 2009/11/18/ PY - 2009/08/24/received PY - 2009/09/14/revised PY - 2009/09/18/accepted PY - 2009/11/20/entrez PY - 2009/11/20/pubmed PY - 2010/5/4/medline SP - 742 EP - 7 JF - Metabolism: clinical and experimental JO - Metabolism VL - 59 IS - 5 N2 - Osteoprotegerin (OPG) is an inhibitor of bone resorption. Circulating levels of OPG seem to be elevated in patients with cardiovascular disorders and diabetes. The relationship between OPG and the metabolic syndrome has never been studied in postmenopausal women. In a population-based study, 382 Iranian postmenopausal women were randomly selected. Cardiovascular risk factors, high-sensitivity C-reactive protein, and OPG were measured. The diabetes classification and the metabolic syndrome definition were based on the criteria of the American Diabetes Association and the National Cholesterol Education Program-Adult Treatment Panel III, respectively. The mean serum OPG level was higher in those with type 2 diabetes mellitus than those without diabetes (4.33 +/- 1.70 vs 3.84 +/- 1.76 pmol/L, P = .016). In multiple logistic regression analysis, type 2 diabetes mellitus showed a significant association with serum OPG levels when adjustments were made for age, high-sensitivity C-reactive protein, and cardiovascular risk factors (odds ratio = 2.21; confidence interval, 1.34-3.66; P = .002). No significant difference was found between the mean serum OPG levels of those with the metabolic syndrome and those without the metabolic syndrome. Mean OPG levels did not differ significantly between subjects with and without hypertension, dyslipidemia, glucose intolerance, or abdominal obesity according to the National Cholesterol Education Program-Adult Treatment Panel III criteria. In conclusion, circulating OPG levels are significantly associated with diabetes, independent of cardiovascular risk factors in postmenopausal women. However, OPG levels have no correlation with the metabolic syndrome or its components. Further studies are warranted to determine the pathophysiologic origin of elevated OPG in type 2 diabetes mellitus. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/19922962/Osteoprotegerin_in_relation_to_type_2_diabetes_mellitus_and_the_metabolic_syndrome_in_postmenopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(09)00409-0 DB - PRIME DP - Unbound Medicine ER -